Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome
NCT ID: NCT02755207
Last Updated: 2020-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2016-04-30
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease
NCT02751060
A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
NCT06955143
Differential Expression and Analysis of Peripheral Plasma Exosome miRNA in Patients With Myocardial Infarction
NCT04127591
The Prognosis of Acute Myocardial Infarction
NCT02737956
Transcriptome Study of Acute Myocardial Infarction
NCT03158597
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We propose to construct the biobank of ACS and evaluate the potential diagnostic value of circulating microRNAs compared with cTnI for suspected ACS patients. All the patients are to be followed up for 6 months. Final diagnosis was made by an expert panel cardiologist, based on all available clinical information including cTnI measurements, ECG, coronary angiography, cardiac exercise tests and information from hospital discharge letters.
The concentrations of microRNAs will be evaluated by quantitative reverse transcription PCR, using highly specific primers and hybridization probes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Suspected ACS group
Patients admitted to the hospital with the diagnosis of ACS
No interventions assigned to this group
Blank control group
Patients admitted to the hospital without the diagnosis of ACS
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Age\>18 years; Informed consent.
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bin He
M.D./Ph.D.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ethics Committee of Xinhua Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XH-16-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.